New drug combo tested to outsmart resistant breast cancer
NCT ID NCT01560416
Summary
This study tested whether adding an experimental drug called ganetespib to the standard hormone therapy fulvestrant could better control advanced breast cancer that had stopped responding to other hormone treatments. It involved 50 people with hormone receptor-positive, HER2-negative metastatic breast cancer. Participants were randomly assigned to receive either fulvestrant alone or the combination, to see if the combo could delay cancer growth longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
DFCI at Faulkner Hospital
Boston, Massachusetts, 02130, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
New Hampshire Oncology and Hematology, P.A.
Concord, New Hampshire, 03301, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.